Generic to Emend Capsules Launched
January 4, 2017 - Sandoz announced the launch of its AB-rated generic to Merck’s Emend® (aprepitant capsules). Emend is indicated for use in combination with other antiemetic agents, for the prevention of acute and delayed nausea and vomiting associated with chemotherapy in patents 12 years of age and older. Emend is also approved for the prevention of postoperative nausea and vomiting in adults. Shipments of Sandoz’ generic have already begun and it is available as 40mg, 80mg, and 125mg capsules. U.S. sales of Emend capsules were approximately $62 million for the twelve months ending October 2016.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by U.S. mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.